Corcept Therapeutics Incorporated (CORT) Cash Flow Statement
Corcept Therapeutics Incorporated (CORT) generated $109.7M of operating cash flow over the twelve months to 2026-06-30, spent $2.8M on capital expenditure and had free cash flow of $106.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CORTCorcept Therapeutics IncorporatedFollow CORT — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- 204.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2009 Dec 09 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | 115.7 | 136.1 | 152.0 | 167.9 | 120.3 | 126.7 | 198.3 | 142.0 | 109.7 | |
| Capital expenditure | — | 0.3 | 1.1 | 1.2 | 0.5 | 0.4 | 0.1 | 2.2 | 0.2 | -2.8 | |
| Free cash flow | — | 115.4 | 135.0 | 150.7 | 167.4 | 119.9 | 126.5 | 196.1 | 141.8 | 106.9 | |
| Share repurchases | — | 23.7 | 31.0 | 9.9 | — | 0.0 | 0.0 | 15.7 | 172.9 | — | |
| Stock-based compensation | — | 23.7 | 29.3 | 33.5 | 42.9 | 42.4 | 48.9 | 61.4 | 84.5 | — |
USD millions · SEC XBRL
Corcept Therapeutics Incorporated — questions
- What is Corcept Therapeutics Incorporated's operating cash flow?
- $109.7M over the twelve months to 2026-06-30.
- How much does Corcept Therapeutics Incorporated spend on capital expenditure?
- $2.8M over the twelve months to 2026-06-30.
- What is Corcept Therapeutics Incorporated's free cash flow?
- $106.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Corcept Therapeutics Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.